Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 122,600 shares, a growth of 63.7% from the February 13th total of 74,900 shares. Based on an average daily trading volume, of 395,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 6.1% of the company’s shares are sold short.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $3.69 on Friday. Aptose Biosciences has a one year low of $2.39 and a one year high of $51.61. The firm has a market cap of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14. The firm has a 50-day simple moving average of $5.13 and a 200-day simple moving average of $8.07.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Wednesday, March 5th. They set a “sell” rating for the company. Finally, Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.00.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.